The promise of retinoids to fight against cancer
The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
Retinoids have a reputation for being both detrimental and beneficial: they are teratogens, but they also have tumour-suppressive capacity. Cell biology and genetics have significantly improved our understanding of the mechanisms that underlie the anti-proliferative action of retinoids. Recent elucidation of the pathways that are activated by retinoids will help us to exploit the beneficial aspects of this powerful class of compounds for cancer therapy and prevention.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Apart from the well-known indications in hypovitaminosis and skin diseases, retinoids have been successfully used in treating cancer”
From Vitamin A Update: Forms, Sources, Kinetics, Detection, Function, Deficiency, Therapeutic Use and Toxicity (2021) · cites this paper as [187]
In the citing paper
“The FDA has approved ATRA to treat cystic acne and several cancers, such as some lymphoma and leukemia”
From Vitamin A Update: Forms, Sources, Kinetics, Detection, Function, Deficiency, Therapeutic Use and Toxicity (2021) · cites this paper as [187]
Citations
Cites
The coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233 · cited 8×
“a | The t(15;17) chromosomal translocation generates the PML–RARα fusion protein that, in contrast to RARα, can efficiently dimerize or oligomerize, thereby recruiting multiple HDAC complexes and leading to ‘super-repression’ of target genes.”
BackgroundInfluentialKamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S.-C., Heyman, R. A., Rose, D. W., Glass, C. K., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81118-6 · Cited by 2,150
Matthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898
ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics
McPherson, K. (2000) · BMJ · doi:10.1136/bmj.321.7261.624 · Cited by 1,570
Hong, W. K., Lippman, S. M., Itri, L. M., Karp, D. D., Lee, J. S., Byers, R. M., Schantz, S. P., Kramer, A. M., Lotan, R., Peters, L. J., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199009203231205 · Cited by 1,365
The retinoids—Biology, chemistry and medicine
(1996) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(97)80793-5 · Cited by 1,178
Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Embryonic retinoic acid synthesis is essential for early mouse post-implantation development
Niederreither, K., Subbarayan, V., Dollé, P., & Chambon, P. (1999) · Nature Genetics · doi:10.1038/7788 · Cited by 1,077
Role of the histone deacetylase complex in acute promyelocytic leukaemia
Lin, R. J., Nagy, L., Inoue, S., Shao, W., Miller, W. H., & Evans, R. M. (1998) · Nature · doi:10.1038/35895 · Cited by 1,062 · cited 1×
“However, high concentrations of HDAC inhibitors (HDACi) can convert even PLZF–RARα into an activator of the RA signalling pathwa”
BackgroundGrignani, F., De Matteis, S., Nervi, C., Tomassoni, L., Gelmetti, V., Cioce, M., Fanelli, M., Ruthardt, M., Ferrara, F. F., Zamir, I., et al. (1998) · Nature · doi:10.1038/35901 · Cited by 1,004 · cited 1×
“However, high concentrations of HDAC inhibitors (HDACi) can convert even PLZF–RARα into an activator of the RA signalling pathwa”
BackgroundThe Retinoids-Biology, Chemistry and Medicine
Wolf, G. (1994) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/60.5.796a · Cited by 998
Nonsteroid nuclear receptors: What Are genetic studies telling us about their role in real life?
Kastner, P., Mark, M., & Chambon, P. (1995) · Cell · doi:10.1016/0092-8674(95)90202-3 · Cited by 995 · cited 1×
“Gene-ablation experiments have shown that nearly all the congenital malformations that are caused by vitamin A deficiency are due to the absence of RAR or RXR function”
PML regulates p53 acetylation and premature senescence induced by oncogenic Ras
Pearson, M., Carbone, R., Sebastiani, C., Cioce, M., Fagioli, M., Saito, S., Higashimoto, Y., Appella, E., Minucci, S., Pandolfi, P. P., et al. (2000) · Nature · doi:10.1038/35018127 · Cited by 847 · cited 1×
“63 ) and regulates the p53 response to oncogenic signal”
Background13-cis-Retinoic Acid in the Treatment of Oral Leukoplakia
Hong, W. K., Endicott, J., Itri, L. M., Doos, W., Batsakis, J. G., Bell, R., Fofonoff, S., Byers, R., Atkinson, E. N., Vaughan, C., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612113152401 · Cited by 819
Docosahexaenoic Acid, a Ligand for the Retinoid X Receptor in Mouse Brain
Urquiza, A. M. D., Liu, S., Sjöberg, M., Zetterström, R. H., Griffiths, W., Sjövall, J., & Perlmann, T. (2000) · Science · doi:10.1126/science.290.5499.2140 · Cited by 742 · cited 1×
“But they also have important physiological functions, particularly in the brai”
BackgroundMuto, Y., Moriwaki, H., Ninomiya, M., Adachi, S., Saito, A., Takasaki, K. T., Tanaka, T., Tsurumi, K., Okuno, M., Tomita, E., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606133342402 · Cited by 668
Cytochrome c Release and Apoptosis Induced by Mitochondrial Targeting of Nuclear Orphan Receptor TR3
Li, H., Kolluri, S. K., Gu, J., Dawson, M. I., Cao, X., Hobbs, P. D., Lin, B., Chen, G.-Q., Lu, J.-S., Lin, F., et al. (2000) · Science · doi:10.1126/science.289.5482.1159 · Cited by 667
The transcriptional role of PML and the nuclear body
Zhong, S., Salomoni, P., & Pandolfi, P. P. (2000) · Nature Cell Biology · doi:10.1038/35010583 · Cited by 577 · cited 1×
“We can only speculate about the possible functions of nuclear bodies in transcription regulatio”
BackgroundPrevention of Skin Cancer in Xeroderma Pigmentosum with the Use of Oral Isotretinoin
Kraemer, K. H., DiGiovanna, J. J., Moshell, A. N., Tarone, R. E., & Peck, G. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806233182501 · Cited by 575
Role of SUMO-1–modified PML in nuclear body formation
Zhong, S., Müller, S., Ronchetti, S., Freemont, P. S., Dejean, A., & Pandolfi, P. P. (2000) · Blood · doi:10.1182/blood.v95.9.2748.009k31a_2748_2752 · Cited by 561 · cited 1×
“PML–RARα interacts with the PML expressed from the intact allele, causing nuclear bodies to disintegrate, and leading to the relocalization of nuclear body proteins in aberrant nuclear structure”
BackgroundHe, L.-Z., Guidez, F., Tribioli, C., Peruzzi, D., Ruthardt, M., Zelent, A., & Pandolfi, P. P. (1998) · Nature Genetics · doi:10.1038/ng0298-126 · Cited by 557 · cited 1×
“However, high concentrations of HDAC inhibitors (HDACi) can convert even PLZF–RARα into an activator of the RA signalling pathwa”
BackgroundRetinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats
Massaro, G. D. C., & Massaro, D. (1997) · Nature Medicine · doi:10.1038/nm0697-675 · Cited by 534 · cited 1×
“In adults, retinoids and/or their cognate receptors are required for the proper functioning of a number of organs, including the skin, lung, liver, and neuronal and immune system”
BackgroundCombinatorial Roles of the Nuclear Receptor Corepressor in Transcription and Development
Jepsen, K., Hermanson, O., Onami, T. M., Gleiberman, A. S., Lunyak, V., McEvilly, R. J., Kurokawa, R., Kumar, V., Liu, F., Seto, E., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00064-7 · Cited by 503 · cited 6×
“a | The t(15;17) chromosomal translocation generates the PML–RARα fusion protein that, in contrast to RARα, can efficiently dimerize or oligomerize, thereby recruiting multiple HDAC complexes and leading to ‘super-repression’ of target genes.”
BackgroundInfluentialWarrell, R. P., He, L.-Z., Richon, V., Calleja, E., & Pandolfi, P. P. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.21.1621 · Cited by 502 · cited 1×
“asp?DrugCode=1%2D11317&DrugName=SODIUM+PHENYLBUTYRATE+ORAL&DrugType=1">sodium phenylbutyrate (which inhibits HDACs non-selectively) and ATRA resulted in complete clinical and cytogenetic remission for 7 months before the patient developed resistance to the treatment, indicating that HDAC inhibition can restore retinoi…”
BackgroundLallemand-Breitenbach, V., Zhu, J., Puvion, F., Koken, M., Honoré, N., Doubeikovsky, A., Duprez, E., Pandolfi, P. P., Puvion, E., Freemont, P., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.12.1361 · Cited by 488 · cited 1×
“asp?DrugCode=A%2D21734&DrugName=ARSENIC+TRIOXIDE+INTRAVEN%2E&DrugType=1">arsenic trioxide (As 2 O 3 ) (Ref”
Bourguet, W., Germain, P., & Gronemeyer, H. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01548-0 · Cited by 482
Self-citationThe function of PML in p53-dependent apoptosis
Guo, A., Salomoni, P., Luo, J., Shih, A., Zhong, S., Gu, W., & Paolo Pandolfi, P. (2000) · Nature Cell Biology · doi:10.1038/35036365 · Cited by 472
Kastner, P., Mark, M., Ghyselinck, N., Krezel, W., Dupé, V., Grondona, J. M., & Chambon, P. (1997) · Development · doi:10.1242/dev.124.2.313 · Cited by 429
Predicting cancer development in oral leukoplakia: ten years of translational research.
Lee, J. J., Hong, W. K., Hittelman, W. N., Mao, L., Lotan, R., Shin, D. M., Benner, S. E., Xu, X. C., Lee, J. S., Papadimitrakopoulou, V., et al. (2000) · PubMed · Cited by 425
Molecular mechanisms of retinoid actions in skin
Fisher, G. J., & Voorhees, J. J. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.9.8801161 · Cited by 421
Crystal Structure of a Heterodimeric Complex of RAR and RXR Ligand-Binding Domains
Bourguet, W., Vivat, V., Wurtz, J.-M., Chambon, P., Gronemeyer, H., & Moras, D. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80424-4 · Cited by 403 · cited 1×
“So, for nearly every receptor isotype, selective agonists or antagonists exist and several three-dimensional structures of RAR and RXR ligand-binding domain (LBD) monomers and heterodimers, some bound to agonists and antagonists, have been solve”
BackgroundSelf-citationTranscriptional cross-talk, the second mode of steroid hormone receptor action
Göttlicher, M., Heck, S., & Herrlich, P. (1998) · Journal of Molecular Medicine · doi:10.1007/s001090050242 · Cited by 388
Dong, Z., Birrer, M. J., Watts, R. G., Matrisian, L. M., & Colburn, N. H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.2.609 · Cited by 386
Impaired Locomotion and Dopamine Signaling in Retinoid Receptor Mutant Mice
Krȩz˙el, W., Ghyselinck, N., Samad, T. A., Dupé, V., Kastner, P., Borrelli, E., & Chambon, P. (1998) · Science · doi:10.1126/science.279.5352.863 · Cited by 349
Altucci, L., Rossin, A., Raffelsberger, W., Reitmair, A., Chomienne, C., & Gronemeyer, H. (2001) · Nature Medicine · doi:10.1038/89050 · Cited by 340
Self-citationNuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway
Caelles, C., González-Sancho, J. M., & Muñoz, A. (1997) · Genes & Development · doi:10.1101/gad.11.24.3351 · Cited by 334
The TRAIL to selective tumor death
French, L. E., & Tschopp, J. (1999) · Nature Medicine · doi:10.1038/5505 · Cited by 323
Lippman, S. M., Lee, J. J., Karp, D. D., Vokes, E. E., Benner, S. E., Goodman, G. E., Khuri, F. R., Marks, R., Winn, R. J., Fry, W., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.8.605 · Cited by 321
Lippman, S. M., Kavanagh, J. J., Paredes-Espinoza, M., Delgadillo-Madrueno, F., Paredes-Casillas, P., Hong, W. K., Holderner, E., & Krakoff, I. H. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.4.241 · Cited by 320
Abnormal spermatogenesis in RXR beta mutant mice.
Kastner, P., Mark, M., Leid, M., Gansmuller, A., Chin, W., Grondona, J. M., Décimo, D., Krezel, W., Dierich, A., & Chambon, P. (1996) · Genes & Development · doi:10.1101/gad.10.1.80 · Cited by 319
A new class of retinoids with selective inhibition of AP-1 inhibits proliferation
Fanjul, A., Dawson, M. I., Hobbs, P. D., Jong, L., Cameron, J. F., Harlev, E., Graupner, G., Lu, X.-P., & Pfahl, M. (1994) · Nature · doi:10.1038/372107a0 · Cited by 313 · cited 1×
“Of particular interest are the observations that 'dissociated' ligands, which maintain the growth-inhibitory effects of ATRA, can block the growth-promoting action of the Kras2 oncogen”
BackgroundCo-regulator recruitment and the mechanism of retinoic acid receptor synergy
Germain, P., Iyer, J., Zechel, C., & Gronemeyer, H. (2002) · Nature · doi:10.1038/415187a · Cited by 308
Self-citationSkin abnormalities generated by temporally controlled RXRα mutations in mouse epidermis
Li, M., Indra, A. K., Warot, X., Brocard, J., Messaddeq, N., Kato, S., Metzger, D., & Chambon, P. (2000) · Nature · doi:10.1038/35036595 · Cited by 301 · cited 1×
“Conditional knockout mice that lack RXRα in their epidermi”
BackgroundAntagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase
Rogatsky, I., Logan, S. K., & Garabedian, M. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2050 · Cited by 297
Leder, A., Kuo, A., Cardiff, R. D., Sinn, E., & Leder, P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.23.9178 · Cited by 293 · cited 1×
“189::srchform:PDQ:">squamous-cell carcinomas and underlying sarcoma”
PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR.
Perez, A., Kastner, P., Sethi, S., Lutz, Y., Reibel, C., & Chambon, P. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05986.x · Cited by 292
Dixon, J. M. (2012) · Medical Entomology and Zoology · Cited by 287
Oligomerization of RAR and AML1 Transcription Factors as a Novel Mechanism of Oncogenic Activation
Minucci, S., Maccarana, M., Cioce, M., De Luca, P., Gelmetti, V., Segalla, S., Di Croce, L., Giavara, S., Matteucci, C., Gobbi, A., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80321-4 · Cited by 285 · cited 1×
“One model postulates that the coiled-coil region of PML is responsible for oligomerization of the fusion protein in APL blasts, resulting in enhanced repression that is caused by the recruitment of several corepressor”
BackgroundMediator complexes and transcription
Rachez, C., & Freedman, L. P. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00209-x · Cited by 281 · cited 1×
“Consequently, transcription is activated by two mechanisms: derepression, caused by chromatin decondensation, and a receptor-dependent increase in the frequency of transcription initiatio”
BackgroundPrevention of Second Primary Tumors by an Acyclic Retinoid in Patients with Hepatocellular Carcinoma
Muto, Y., Moriwaki, H., & Saito, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904013401315 · Cited by 265
Motzer, R. J., Murphy, B. A., Bacik, J., Schwartz, L. H., Nanus, D. M., Mariani, T., Loehrer, P., Wilding, G., Fairclough, D. L., Cella, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2972 · Cited by 264
Meyskens, F. L., Surwit, E., Moon, T. E., Childers, J. M., Davis, J. R., Dorr, R. T., Johnson, C. S., & Alberts, D. S. (1994) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/86.7.539 · Cited by 263
Methylation and Silencing of the Retinoic Acid Receptor- 2 Gene in Breast Cancer
Widschwendter, M., Berger, J., Hermann, M., Muller, H. M., Amberger, A., Zeschnigk, M., Widschwendter, A., Abendstein, B., Zeimet, A. G., Daxenbichler, G., et al. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.10.826 · Cited by 259
The TRAP/SMCC/Mediator complex and thyroid hormone receptor function
Ito, M., & Roeder, R. G. (2001) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(00)00355-6 · Cited by 256 · cited 1×
“Consequently, transcription is activated by two mechanisms: derepression, caused by chromatin decondensation, and a receptor-dependent increase in the frequency of transcription initiatio”
BackgroundChen, J. Y., Penco, S., Ostrowski, J., Balaguer, P., Pons, M., Starrett, J. E., Reczek, P., Chambon, P., & Gronemeyer, H. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07102.x · Cited by 255 · cited 2×
“Preliminary results show that the PKA–rexinoid crosstalk affects the TRAIL signalling pathway and can induce differentiation of t(11;17) APL blasts that are refractory to ATRA action (L.”
BackgroundSelf-citationActivation of Retinoid X Receptors Induces Apoptosis in HL-60 Cell Lines
Nagy, L., Thomázy, V. A., Shipley, G. L., Fésüs, L., Lamph, W., Heyman, R. A., Chandraratna, R. A. S., & Davies, P. J. A. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.7.3540 · Cited by 241
Lin, R. J., & Evans, R. M. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80322-6 · Cited by 232 · cited 1×
“3 ) predicts that PML–RARα forms homodimers that recruit two corepressor molecules, unlike the RAR–RXR heterodimer, which recruits only one corepresso”
BackgroundWan, Y.-J. Y., An, D., Cai, Y., Repa, J. J., Hung-Po Chen, T., Flores, M., Postic, C., Magnuson, M. A., Chen, J., Chien, K. R., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.12.4436-4444.2000 · Cited by 228
Leptomeningeal carcinomatosis: How does cancer reach the pia-arachnoid?
Kokkoris, C. P. (1983) · Cancer · doi:10.1002/1097-0142(19830101)51:1<154::aid-cncr2820510130>3.0.co;2-k · Cited by 201
Benner, S. E., Pajak, T. F., Lippman, S. M., Earley, C., & Hong, W. K. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.2.140 · Cited by 201
Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand.
Gottardis, M. M., Bischoff, E. D., Shirley, M. A., WAGONER, M., Lamph, W. W., & Heyman, R. A. (1996) · PubMed · Cited by 199
Two distinct actions of retinoid-receptor ligands
Chen, J.-Y., Clifford, J., Zusi, C., Starrett, J., Tortolani, D., Ostrowski, J., Reczek, P. R., Chambon, P., & Gronemeyer, H. (1996) · Nature · doi:10.1038/382819a0 · Cited by 194
Self-citationInitial clinical trial of a selective retinoid X receptor ligand, LGD1069.
Miller, V. A., Benedetti, F. M., Rigas, J. R., Verret, A. L., Pfister, D. G., Straus, D., Kris, M. G., Crisp, M., Heyman, R., Loewen, G. R., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.790 · Cited by 185
Intracellular Signaling by 14-hydroxy-4,14- Retro -Retinol
Buck, J., Derguini, F., Levi, E., Nakanishi, K., & Hämmerling, U. (1991) · Science · doi:10.1126/science.1749937 · Cited by 182
Minucci, S., Nervi, C., Coco, F. L., & Pelicci, P. G. (2001) · Oncogene · doi:10.1038/sj.onc.1204336 · Cited by 163 · cited 1×
“Now, evidence is accumulating that aberrant recruitment of HDACs is common in several types of AML and that HDACis restore responsivity to retinoids (reviewed in Ref”
BackgroundNovogrodsky, A., Dvir, A., Ravid, A., Shkolnik, T., Stenzel, K. H., Rubin, A. L., & Zaizov, R. (1983) · Cancer · doi:10.1002/1097-0142(19830101)51:1<9::aid-cncr2820510104>3.0.co;2-4 · Cited by 159 · cited 1×
“Seventeen years ago — before its mechanism of action could even be guessed at — butyrate treatment of an AML patient led to partial remissio”
BackgroundRole of PML and PML-RARα in Mad-Mediated Transcriptional Repression
Khan, M. M., Nomura, T., Kim, H., Kaul, S. C., Wadhwa, R., Shinagawa, T., Ichikawa-Iwata, E., Zhong, S., Pandolfi, P. P., & Ishii, S. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00257-x · Cited by 145
Nerve growth factor acts via retinoic acid synthesis to stimulate neurite outgrowth
Corcoran, J. P. T., & Maden, M. (1999) · Nature Neuroscience · doi:10.1038/7214 · Cited by 144
All- retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia
Fenaux, P., Chomienne, C., & Degos, L. (2001) · Seminars in Hematology · doi:10.1016/s0037-1963(01)90002-2 · Cited by 138 · cited 1×
“This might reduce the adverse effects of ATRA, known as retinoic acid syndrome ( Box 4”
BackgroundRetinoic Acid Redifferentiation Therapy for Thyroid Cancer
Schmutzler, C., & Köhrle, J. (2000) · Thyroid · doi:10.1089/thy.2000.10.393 · Cited by 137
Bonavida, B., Ng, C. P., Jazirehi, A. R., Schiller, G. J., & Mizutani, Y. (1999) · International Journal of Oncology · doi:10.3892/ijo.15.4.793 · Cited by 135
Vosti, G. J., Willett, F. M., & Jawetz, E. (1961) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt19612129 · Cited by 135
List, H.-J., Lauritsen, K. J., Reiter, R., Powers, C., Wellstein, A., & Riegel, A. T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102397200 · Cited by 134 · cited 1×
“cgi?l=8202">AIB1 ) for oestrogen-mediated growth of MCF7 breast cancer cell”
BackgroundVitamin A--functions, dietary requirements and safety in humans.
GERSTER, H. (1997) · PubMed · Cited by 129
Redifferentiation therapy-induced radioiodine uptake in thyroid cancer.
Grünwald, F., Menzel, C., Bender, H., PALMEDO, H., Otte, R., Fimmers, R., Risse, J. H., & Biersack, H. J. (1998) · PubMed · Cited by 124
Retinoic acid receptor-β: an endogenous inhibitor of the perinatal formation of pulmonary alveoli
MASSARO, G. D., Massaro, D. J., Chan, W., Clerch, L. B., Ghyselinck, N. B., Chambon, P., & Chandraratna, R. A. S. (2000) · Physiological Genomics · doi:10.1152/physiolgenomics.2000.4.1.51 · Cited by 123
Khuri, F. R., Rigas, J. R., Figlin, R. A., Gralla, R. J., Shin, D. M., Munden, R. F., Fox, N., Huyghe, M. R., Kean, Y., Reich, S. D., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2626 · Cited by 121
c-Jun Can Mediate Androgen Receptor-induced Transactivation
Bubulya, A., Wise, S., Shen, X.-Q., Burmeister, L. A., & Shemshedini, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.40.24583 · Cited by 121
Shin, D. M., Khuri, F. R., Murphy, B. A., Garden, A. S., Clayman, G. L., Francisco, M., Liu, D., Glisson, B. S., Ginsberg, L. E., Papadimitrakopoulou, V. A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.12.3010 · Cited by 120
Dupé, V., Ghyselinck, N. B., Thomázy, V. A., Nagy, L., Davies, P. J., Chambon, P., & Mark, M. P. (1999) · Developmental Biology · doi:10.1006/dbio.1998.9176 · Cited by 119 · cited 1×
“The AML1–ETO fusion protein, which originates from a t(8;21) chromosomal rearrangement in a subtype of AML patients, is an HDAC-dependent repressor of retinoid signalling(78).”
BackgroundBovenzi, V., & Momparler, R. L. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800100294 · Cited by 118
Zhou, X., Shen, X.-Q., & Shemshedini, L. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.2.0237 · Cited by 118
Differentiating agents in pediatric malignancies: Retinoids in neuroblastoma
Reynolds, C. P. (2000) · Current Oncology Reports · doi:10.1007/s11912-000-0104-y · Cited by 113
Camerini, T., Mariani, L., Palo, G. D., Marubini, E., Mauro, M. G. D., DeCensi, A., Costa, A., & Veronesi, U. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1664 · Cited by 112
RAR‐independent RXR signaling induces t(15;17) leukemia cell maturation
Benoit, G., Altucci, L., Flexor, M., Ruchaud, S., Lillehaug, J., Raffelsberger, W., Gronemeyer, H., & Lanotte, M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.24.7011 · Cited by 111 · cited 1×
“Indeed, it has been shown that rexinoid agonists can induce differentiation programmes in the presence of elevated cyclic AMP levels independently of RAR signallin”
BackgroundSelf-citationLin, B., Chen, G., Xiao, D., Kolluri, S. K., Cao, X., Su, H., & Zhang, X.-K. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.3.957-970.2000 · Cited by 111
Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia
Pandolfi, P. P. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.769 · Cited by 110
Drug Approval Summaries: Arsenic Trioxide, Tamoxifen Citrate, Anastrazole, Paclitaxel, Bexarotene
Cohen, M. H., Hirschfeld, S., Honig, S. F., Ibrahim, A., Johnson, J. R., O'Leary, J. J., White, R. M., Williams, G. A., & Pazdur, R. (2001) · The Oncologist · doi:10.1634/theoncologist.6-1-4 · Cited by 102
Therapeutic potential of selective modulators of nuclear receptor action
Resche-Rigon, M., & Gronemeyer, H. (1998) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(98)80126-9 · Cited by 97 · cited 1×
“Although the mechanistic basis of the anti-AP1 activity of retinoids has remained elusive, despite the proposal of several distinct mechanism”
BackgroundSelf-citationSun, S., Yue, P., Hong, W. K., & Lotan, R. (2000) · PubMed · Cited by 97
Genomic Organization and Transcriptional Regulation of Human Apo2/TRAIL Gene
Gong, B., & Almasan, A. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3872 · Cited by 94 · cited 1×
“cgi?Q=ifnb*%20not%20il6&ORG=Hs">β also induce TRAIL expressio”
Cheng, G.-X., Zhu, X., Men, X.-Q., Wang, L., Huang, Q. H., Jin, X. L., Xiong, S.-M., Zhu, J., Guo, W.-M., Chen, J.-Q., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6318 · Cited by 91
Stage-dependent responses of the developing lung to retinoic acid signaling.
Mollard, R., Ghyselinck, N., Wendling, O., Chambon, P., & Mark, M. (2000) · International Journal of Developmental Biology · doi:10.1387/ijdb.11032179 · Cited by 90
Chemoprevention of Skin Cancer in Xeroderma Pigmentosum
Kraemer, K. H., DiGiovanna, J. J., & Peck, G. L. (1992) · The Journal of Dermatology · doi:10.1111/j.1346-8138.1992.tb03766.x · Cited by 88
Imai, T., Jiang, M., Kastner, P., Chambon, P., & METZGER, D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.071056098 · Cited by 87
Greenhalgh, D. A., Welty, D. J., Player, A. N., & Yuspa, S. H. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.2.643 · Cited by 86 · cited 1×
“cgi?l=15461"> Hras1 is an early genetic change in mouse skin carcinogenesis that is associated with benign tumour formatio”
BackgroundArnhold, T., Tzimas, G., Wittfoht, W., Plonait, S. L., & Nau, H. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00408-0 · Cited by 86
Pearce, D., Matsui, W. H., Miner, J. N., & Yamamoto, K. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30081 · Cited by 85
Sun, S., Yue, P., Mao, L., Dawson, M. I., Shroot, B., Lamph, W. W., Heyman, R. A., Chandraratna, R. A. S., Shudo, K., Hong, W. K., et al. (2000) · PubMed · Cited by 84
Zhang, D., Holmes, W. F., Wu, S., Soprano, D. R., & Soprano, K. J. (2000) · Journal of Cellular Physiology · doi:10.1002/1097-4652(200010)185:1<68::aid-jcp6>3.0.co;2-d · Cited by 83
Zhang, D., Holmes, W. F., Wu, S., Soprano, D. R., & Soprano, K. J. (2000) · Journal of Cellular Physiology · doi:10.1002/1097-4652(200010)185:1<1::aid-jcp1>3.0.co;2-o · Cited by 83
Successful topical treatment of oral lichen planus and leukoplakias with fenretinide (4-HPR)
Tradati, N., Chiesa, F., Rossi, N., Grigolato, R., Formelli, F., Costa, A., & Palo, G. D. (1994) · Cancer Letters · doi:10.1016/0304-3835(94)90385-9 · Cited by 79
Duvic, M. A., Friedman‐Kien, A. E., Looney, D. J., Miles, S. A., Myskowski, P. L., Scadden, D. T., Roenn, J. V., Galpin, J. E., Groopman, J. E., Loewen, G. R., et al. (2000) · Archives of Dermatology · doi:10.1001/archderm.136.12.1461 · Cited by 78
Wong, C.-W., & Privalsky, M. L. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.10.5724 · Cited by 74 · cited 1×
“The gene programme(s) that is regulated by RARβ is entirely unknown, but it is tempting to speculate that it might be related to two functionalities that distinguish RARβ from the other receptors: first, RARβ interacts only inefficiently with co-repressor”
BackgroundUnique anti-activator protein-1 activity of retinoic acid receptor beta.
Lin, F., Xiao, D., Kolluri, S. K., & Zhang, X. (2000) · PubMed · Cited by 68
Côté, S., Zhou, D.-C., Bianchini, A., Nervi, C., Gallagher, R. E., & Miller, W. H. (2000) · Blood · doi:10.1182/blood.v96.9.3200 · Cited by 65
Retinoic acid rescues inner ear defects in Hoxa1 deficient mice
Pasqualetti, M., Neun, R., Davenne, M., & Rijli, F. M. (2001) · Nature Genetics · doi:10.1038/ng702 · Cited by 64
Redifferentiation therapy with retinoic acid in follicular thyroid cancer.
Grünwald, F., Pakos, E. E., Bender, H., Menzel, C., Otte, R., PALMEDO, H., Pfeifer, U., & Biersack, H. J. (1998) · PubMed · Cited by 64
DiGiovanna, J. J. (2001) · Dermatologic Clinics · doi:10.1016/s0733-8635(05)70237-0 · Cited by 62
Dawson, M., Hobbs, P. D., Peterson, V. J., Leid, M. E., Lange, C. W., Feng, K. C., Chen, G.-Q., Gu, J., Li, H., Kolluri, S. K., et al. (2001) · PubMed · Cited by 61
Retinoid chemoprevention in patients at high risk for skin cancer*
DiGiovanna, J. J. (2001) · Medical and Pediatric Oncology · doi:10.1002/mpo.1131 · Cited by 60
EMERGING NEW THERAPIES FOR CUTANEOUS T-CELL LYMPHOMA
Duvic, M. A., & Cather, J. C. (2000) · Dermatologic Clinics · doi:10.1016/s0733-8635(05)70155-8 · Cited by 59
Kelly, W. K., Osman, I., Reuter, V. E., Curley, T., Heston, W. D. W., Nanus, D. M., & Scher, H. I. (2000) · PubMed · Cited by 57
Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer
DeCensi, A., & Costa, A. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00040-x · Cited by 55
Anhydroretinol induces oxidative stress and cell death.
Chen, Y., Buck, J., & Derguini, F. (1999) · PubMed · Cited by 53
Topical tretinoin in actinic keratosis and basal cell carcinoma
Peck, G. L. (1986) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(86)70241-7 · Cited by 52
Sun, S., Yue, P., Hong, W. K., & Lotan, R. (2000) · PubMed · Cited by 52
Phase I trial of 9-cis retinoic acid in adults with solid tumors.
Kurie, J. M., Lee, J. S., Griffin, T., Lippman, S. M., Drum, P., Thomas, M. P., Weber, C., Bader, M., Massimini, G., & Hong, W. K. (1996) · PubMed · Cited by 51
Dong, G., Loukinova, E. B., Smith, C. W., Chen, Z., & Waes, C. V. (1997) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(1997)28/29+<174::aid-jcb21>3.0.co;2-g · Cited by 49
Lawrence, J. A., Adamson, P. C., Caruso, R. C., Chow, C., Kleiner, D. E., Murphy, R. F., Venzon, D. J., Shovlin, M., Noone, M., Merino, M. J., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2754 · Cited by 49
Benoit, G. R., Flexor, M., Besançon, F., Altucci, L., Rossin, A., Hillion, J., Balajthy, Z., Legrès, L., Ségal-Bendirdjian, E., Gronemeyer, H., et al. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.7.0654 · Cited by 48 · cited 1×
“The AML1–ETO fusion protein, which originates from a t(8;21) chromosomal rearrangement in a subtype of AML patients, is an HDAC-dependent repressor of retinoid signalling(78).”
BackgroundSelf-citationEffects of novel phenylretinamides on cell growth and apoptosis in bladder cancer.
Clifford, J. L., Sabichi, A. L., Zou, C., Yang, X., Steele, V. E., Kelloff, G. J., Lotan, R., & Lippman, S. M. (2001) · PubMed · Cited by 48
Boisnic, S., Branchet, M., Pascal, F., Slama, L. B., Rostin, M., & Szpirglas, H. (1994) · PubMed · Cited by 47
Holmes, W. F., Dawson, M. I., Soprano, D. R., & Soprano, K. J. (2000) · Journal of Cellular Physiology · doi:10.1002/1097-4652(200010)185:1<61::aid-jcp5>3.0.co;2-0 · Cited by 47 · cited 1×
“However, this activity does not explain all their growth-inhibitory and apoptogenic effects because they are active in retinoid-resistant cells and retinoid antagonists do not completely block their activit”
BackgroundBexarotene ligand pharmaceuticals.
Hurst, R. E. (2000) · PubMed · Cited by 44
Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention.
Shin, D. M., Xu, X. C., Lippman, S. M., Lee, J. J., Lee, J. S., Batsakis, J. G., Ro, J. Y., Martin, J. W., Hittelman, W. N., Lotan, R., et al. (1997) · PubMed · Cited by 40
Ma, X., Karra, S., Guo, W., Lindner, D. J., Hu, J., Angell, J. E., Hofmann, E. R., Reddy, S. P., & Kalvakolanu, D. V. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100380200 · Cited by 40
Agarwal, V. R., Bischoff, E. D., Hermann, T. W., & Lamph, W. W. (2000) · PubMed · Cited by 36
Sakaue, M., Adachi, H., Dawson, M. I., & Jetten, A. M. (2001) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400818 · Cited by 30
Gamage, S. D., Bischoff, E. D., Burroughs, K. D., Lamph, W. W., Gottardis, M. M., Walker, C. L., & Fuchs‐Young, R. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38955-4 · Cited by 29
Fenretinide and cancer prevention
Torrisi, R., & DeCensi, A. (2000) · Current Oncology Reports · doi:10.1007/s11912-000-0077-x · Cited by 28
Fenretinide Therapy in Prostate Cancer: Effects on Tissue and Serum Retinoid Concentration
Christina Thaller, B., Shalev, M., Frolov, A., Gregor Eichele, C., Thompson, T. C., Williams, R. H., Dillioğlugil, Ö., & Kadmon, D. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3804 · Cited by 27
Progressive 13-cis-retinoic acid dosage in the treatment of oral leukoplakia
Toma, S., Mangiante, P., Margarino, G., Nicolò, G., & Palumbo, R. (1992) · European Journal of Cancer Part B Oral Oncology · doi:10.1016/0964-1955(92)90039-4 · Cited by 26
Park, T. K., Lee, J. P., Kim, S. N., Choi, S. M., Kudelka, A. P., & Kavanagh, J. J. (1998) · PubMed · Cited by 25
Roenn, J. H. V., & Cianfrocca, M. E. (2001) · Cancer treatment and research · doi:10.1007/978-1-4615-1601-9_5 · Cited by 21
AIDS-related Kaposi's sarcoma: current treatment options, future trends.
Mitsuyasu, R. T. (2000) · PubMed · Cited by 19
Miller, W. H., Reyno, L. M., Loewen, G. R., Huan, S. D., Winquist, E., Moore, M. J., Cato, A. C. B., Jaunakais, D., Truglia, J. A., Matthews, S. W., et al. (2000) · Annals of Oncology · doi:10.1023/a:1026579400806 · Cited by 18
Dezube, B. J. (2000) · Archives of Dermatology · doi:10.1001/archderm.136.12.1554 · Cited by 15
Ruidi, C., Aihua, D., Peiyu, B., Zhongru, G., Huazao, L., Shifeng, S., Han, R., & Shiping, X. (1997) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(1997)28/29+<140::aid-jcb16>3.0.co;2-l · Cited by 15
Regine, W. F., Valentino, J. P., SLOAN, D. A., Patel, P., Pittard, M. Q., Kenady, D. E., & Mohiuddin, M. (1999) · Head & Neck · doi:10.1002/(sici)1097-0347(199909)21:6<566::aid-hed11>3.0.co;2-h · Cited by 14
DiSilvestro, P., DiSilvestro, J. M., Lernhardt, W., Pfahl, M., & Mannel, R. S. (2001) · Journal of Lower Genital Tract Disease · doi:10.1046/j.1526-0976.2001.51007.x · Cited by 13
The biology of acute promyelocytic leukemia
Mann, K. K., Shao, W., & Miller, W. H. (2001) · Current Oncology Reports · doi:10.1007/s11912-001-0052-1 · Cited by 13
Recchia, F., Sica, G., Filippis, S. D., Rosselli, M., Saggio, G., Guerriero, G., Pompili, P., & Rea, S. (2000) · PubMed · Cited by 13
Bayesian monitoring of a phase 2 chemoprevention trial in high-risk cohorts for prostate cancer
Weiss, H. L., Urban, D. A., Grizzle, W., Cronin, K. A., Freedman, L. S., Kelloff, G. J., & Lieberman, R. (2001) · Urology · doi:10.1016/s0090-4295(00)00979-1 · Cited by 12
Veronesi, U., & DeCensi, A. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.7.486 · Cited by 12
Treatment of Kaposi's sarcoma.
Jh, V. R., & Cianfrocca, M. E. (2001) · PubMed · Cited by 10
Branchet, M., Boisnic, S., Pascal, F., Slama, L. B., Rostin, M., & Szpirglas, H. (1994) · PubMed · Cited by 8
Hot on the TRAIL of acute promyelocytic leukemia
Zelent, A. (2001) · Nature Medicine · doi:10.1038/89031 · Cited by 6
Somos, S., & Farkas, B. (2000) · PubMed · Cited by 6
(2001) · PubMed
Research works printed but not linked: 1
- Moon, R. C., Mehta, R. G. & Rao, K. J. V. N. in The Retinoids (eds Sporn, M. B., Roberts, A. B. & Goodman, D. S.) 573–595 (Raven, New York, 1994).
Cited by
Signal integration by JNK and p38 MAPK pathways in cancer development
Wagner, E. F., & Nebreda, Á. R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2694 · Cited by 2,586
“The JNK/JUN pathway regulates a plethora of target genes that contain AP1-binding sites, including genes that control the cell cycle, as well as survival and apoptosis, metalloproteinases and nuclear hormone receptors, such as retinoid receptor”
BackgroundAP-1: a double-edged sword in tumorigenesis
Eferl, R., & Wagner, E. F. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1209 · Cited by 2,242
“In at least some of these cases, the tumour-suppressive activity of retinoic acids is mediated by transrepression of AP-1 (Ref”
BackgroundPrinciples for modulation of the nuclear receptor superfamily
Gronemeyer, H., Gustafsson, J.-Å., & Laudet, V. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1551 · Cited by 1,226
“Whether and how this distinct characteristic of RARβ is linked to its presumptive role as a tumour supressor remains to be established (see Ref”
BackgroundSelf-citationNuclear retinoid receptors and the transcription of retinoid-target genes
Bastien, J., & Rochette-Egly, C. (2004) · Gene · doi:10.1016/j.gene.2003.12.005 · Cited by 773
“The repressive effect of retinoids on AP-1 activity has been correlated with their antitumor activity and the importance of this cross-talk for growth control is increasingly recognized (Altucci and Gronemeyer, 2001b).”
BackgroundInfluentialThe Lipophilic Bullet Hits the Targets: Medicinal Chemistry of Adamantane Derivatives
Wanka, L., Iqbal, K., & Schreiner, P. R. (2013) · Chemical Reviews · doi:10.1021/cr100264t · Cited by 696
Metadata
- Authors
- Altucci, L., & Gronemeyer, H.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Venue
- Nature Reviews Cancer
- Published
- 2001-12
- Volume
- 1
- Issue
- 3
- Pages
- 181-193
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1964224609
- Cited by
- 773
- References
- 147
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 16 · 2023: 18 · 2022: 12 · 2021: 16 · 2020: 20 · 2019: 19 · 2018: 20 · 2017: 28 · 2016: 25 · 2015: 36 · 2014: 25 · 2013: 32 · 2012: 47
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Institut National de la Santé et de la Recherche Médicale
- Centre National de la Recherche Scientifique
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- retinoids, cancer therapy, cancer prevention, tumor suppression, antiproliferative mechanism, teratogenicity, cell proliferation
- MeSH terms
- Antineoplastic Agents, Cell Differentiation, Forecasting, Humans, Models, Biological, Morphogenesis, Neoplasm Proteins, Neoplasms, Retinoids, Skin Neoplasms, Structure-Activity Relationship, Vitamin A, Leukemia, Promyelocytic, Acute, Oncogene Proteins, Fusion, Transcriptional Activation, Gene Expression Regulation, Neoplastic, Anticarcinogenic Agents, Apoptosis, Receptors, Retinoic Acid, Transcription Factor AP-1, Dimerization, Receptor Cross-Talk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.